Prior to Pre-Reg | Prior to Reg* | Day 1 of each cycle of mFOLFIR-INOX* | RT (day 1 to day 5) (Arm 2 only) | Surgery | Day 1 of each cycle of FOLFOX * | Post Tx Follow- up** | |
---|---|---|---|---|---|---|---|
Tests & Observations | |||||||
History and physical, weight, PS *** | X [1] | X [1] | X [1] | X [1] | X [1] | ||
Pulse, BP | X [1] | X [1] | X [1] | X [1] | X [1] | ||
Height | X [1] | ||||||
Adverse Event Assessment (CTCAE) † | X [1] | X [1] | X [1] | D [1] | X [1] | ||
Adverse Event Assessment (PRO-CTCAE) †† | X [2] | X | X | D | X | ||
Registration QOL/Mental Well-being/Physical Well-being/Fatigue | X [2] | ||||||
Laboratory Studies | |||||||
CBC, Differential, Platelets | X | X | X | X | X | X | |
Chemistry (Serum Creatinine, Electrolytes, AST, ALT, Alk. Phos., Albumin, Total Bilirubin) | X | X | X | X | X | X | |
Pregnancy Test (#) | X | ||||||
CA 19–9 | A | A | A | A | A | X | |
RT Planning | |||||||
EUS with Fiducial Placement for RT | B | ||||||
Staging | |||||||
Staging CT Scan of Chest or Chest X-ray/CT or MRI of Abdomen | X [3] | C [3] | C [3] | C [3] | C [3] | X [3] | |
Central Radiographic Review | C | C | |||||
Central Pathology Review | X [4] | ||||||
Optional Correlative studies: For patients who consent to participate | |||||||
Blood specimen sample (A021501-PP1) | Between Registration and C1D1. See Additional file 1: Section 6.2. | ||||||
Imaging (A021501-IM1) | See Additional file 1: Section 6.4.2 for CT images submission time points and requirements. |